Research sponsored by iCureASPS published: Is ASPS a target for Halofuginone therapy?

Cure Alveolar Soft Part Sarcoma International is very proud to announce the publication of a study that was supported by donations through our organization. The new study appears in the scientific journal ”Neoplasia”. It focuses on genes which are expressed in alveolar soft part sarcoma and in the normal cells surrounding the tumor. Those cells express essential genes for tumor proliferation and can be inhibited by Halofuginone.

Halofuginone belongs to the family of drugs called quinazolinone alkaloids. It is one of the analogues of the molecule febrifugine, which is the active component in the extract from the roots of a plant that was used in China to treat malarial fever and in the poultry industry to treat Coccidiosis in chickens. In the context of cancer, Halofuginone is studied for its ability to slow the growth of connective tissue and prevent the growth of new blood vessels to a solid tumor.

Dr. Mark Pines, the author of the study discovered the therapeutic effects of Halofuginone. In the first part of the study, Dr. Pines measures the expression of Halofuginone gene targets in ASPS tumors and in the second part of that study he tests Halofuginone’s effects on renal tumor that carries the ASPS translocation: ASPL-TFE3. Drug treatment inhibits tumor growth in mice and reduces the expression of tumor promoting genes.

We are proud to support Dr. Mark Pines’ research, and hope to continue these studies in order to find out if ASPS may eventually be cured by Halofuginone.

To read Dr. Pines study please see: Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: A novel target for treatment?


Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)